Wells Fargo & Company Reiterates Market Perform Rating for Qiagen N.V. (NASDAQ:QGEN)
Qiagen N.V. (NASDAQ:QGEN)‘s stock had its “market perform” rating reaffirmed by analysts at Wells Fargo & Company in a research report issued on Thursday, July 13th. They currently have a $31.00 price target on the stock, up from their prior price target of $28.00. Wells Fargo & Company’s price target would indicate a potential downside of 3.40% from the stock’s previous close.
A number of other research firms have also weighed in on QGEN. Evercore ISI increased their price objective on shares of Qiagen N.V. from $30.00 to $31.50 and gave the stock an “outperform” rating in a research note on Thursday, May 4th. TheStreet upgraded shares of Qiagen N.V. from a “c” rating to a “b” rating in a research note on Monday, June 5th. BidaskClub lowered shares of Qiagen N.V. from a “strong-buy” rating to a “buy” rating in a research note on Saturday, June 10th. Commerzbank Ag reiterated a “buy” rating on shares of Qiagen N.V. in a research note on Monday, May 15th. Finally, DZ Bank AG reiterated a “neutral” rating on shares of Qiagen N.V. in a research note on Monday, May 15th. Eight equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Qiagen N.V. presently has an average rating of “Hold” and an average target price of $33.19.
Shares of Qiagen N.V. (NASDAQ QGEN) opened at 32.09 on Thursday. The company has a market cap of $7.32 billion, a P/E ratio of 98.13 and a beta of 1.14. The company’s 50 day moving average is $33.97 and its 200 day moving average is $31.03. Qiagen N.V. has a 12 month low of $24.86 and a 12 month high of $35.26.
Qiagen N.V. (NASDAQ:QGEN) last issued its quarterly earnings results on Thursday, July 27th. The company reported $0.30 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.28 by $0.02. Qiagen N.V. had a net margin of 5.44% and a return on equity of 11.04%. The business had revenue of $349 million for the quarter, compared to analyst estimates of $353.09 million. During the same quarter in the prior year, the business posted $0.24 EPS. Qiagen N.V.’s revenue for the quarter was up 4.4% compared to the same quarter last year. On average, equities research analysts predict that Qiagen N.V. will post $1.23 EPS for the current fiscal year.
WARNING: This story was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this story on another site, it was illegally stolen and republished in violation of international copyright & trademark laws. The legal version of this story can be viewed at https://www.thecerbatgem.com/2017/08/08/qiagen-n-v-nasdaqqgen-rating-reiterated-by-wells-fargo-co-updated-updated-updated.html.
Institutional investors have recently bought and sold shares of the stock. FNY Managed Accounts LLC bought a new position in Qiagen N.V. during the first quarter valued at about $103,000. Oppenheimer Asset Management Inc. bought a new position in Qiagen N.V. during the first quarter valued at about $114,000. Quadrant Capital Group LLC increased its position in Qiagen N.V. by 403.4% in the first quarter. Quadrant Capital Group LLC now owns 5,517 shares of the company’s stock valued at $154,000 after buying an additional 4,421 shares during the last quarter. Rehmann Capital Advisory Group bought a new position in Qiagen N.V. during the first quarter valued at about $207,000. Finally, Prudential Financial Inc. bought a new position in Qiagen N.V. during the first quarter valued at about $207,000. 59.84% of the stock is currently owned by institutional investors and hedge funds.
Qiagen N.V. Company Profile
QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials.
Receive News & Stock Ratings for Qiagen N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen N.V. and related stocks with our FREE daily email newsletter.